Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H28N2O5 |
| Molecular Weight | 376.4467 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(=O)N(C1=CC=CC=C1)C2(CCN(CCC(=O)OC)CC2)C(=O)OC
InChI
InChIKey=ZTVQQQVZCWLTDF-UHFFFAOYSA-N
InChI=1S/C20H28N2O5/c1-4-17(23)22(16-8-6-5-7-9-16)20(19(25)27-3)11-14-21(15-12-20)13-10-18(24)26-2/h5-9H,4,10-15H2,1-3H3
Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. ULTIVA is a µ-opioid agonist with rapid onset and peak effect, and short duration of action. The
µ-opioid activity of ULTIVA is antagonized by opioid antagonists such as naloxone. ULTIVA is indicated for IV administration:
1. As an analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures.
2. For continuation as an analgesic into the immediate postoperative period in adult patients under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting.
3. As an analgesic component of monitored anesthesia care in adult patients.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL233 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | ULTIVA Approved UseULTIVA is indicated for IV administration: 1.As an analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. 2.For continuation as an analgesic into the immediate postoperative period in adult patients under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting. 3.As an analgesic component of monitored anesthesia care in adult patients. Launch Date8.371296E11 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
194 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14766712 |
6 μg/kg/h 1 times / day other, intravenous dose: 6 μg/kg/h route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL ACID blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
14 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14766712 |
6 μg/kg/h 1 times / day other, intravenous dose: 6 μg/kg/h route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
8080 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14766712 |
6 μg/kg/h 1 times / day other, intravenous dose: 6 μg/kg/h route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL ACID blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
745 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14766712 |
6 μg/kg/h 1 times / day other, intravenous dose: 6 μg/kg/h route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.48 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14766712 |
6 μg/kg/h 1 times / day other, intravenous dose: 6 μg/kg/h route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL ACID blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
11.4 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14766712 |
6 μg/kg/h 1 times / day other, intravenous dose: 6 μg/kg/h route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
30% |
0.5 μg/kg/min 1 times / day other, intravenous dose: 0.5 μg/kg/min route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Total intravenous anesthesia (TIVA) and balanced anesthesia with short-acting anesthetics for ENT surgery in children]. | 1999 |
|
| TIVA with propofol and remifentanil. | 1999 May |
|
| Remifentanil, propofol or both for conscious sedation during eye surgery under regional anaesthesia. | 1999 Nov |
|
| [Stand-by and conscious sedation--possibilities and limits of anesthesiological management]. | 2001 |
|
| Effects of fentanyl, alfentanil, remifentanil and sufentanil on loss of consciousness and bispectral index during propofol induction of anaesthesia. | 2001 Apr |
|
| Influence of hypotensive and normotensive anesthesia on platelet aggregability and hemostatic markers in orthognathic surgery. | 2001 Aug 1 |
|
| Small doses of remifentanil or sufentanil for blunting cardiovascular changes induced by tracheal intubation: a double-blind comparison. | 2001 Feb |
|
| [Computer simulation and pharmacoeconomics. Computer simulation as an aid for the analysis of operating room efficiency: an example]. | 2001 Feb |
|
| Influence of hemorrhagic shock on remifentanil: a pharmacokinetic and pharmacodynamic analysis. | 2001 Feb |
|
| Assessment of depth of anesthesia and postoperative respiratory recovery after remifentanil- versus alfentanil-based total intravenous anesthesia in patients undergoing ear-nose-throat surgery. | 2001 Feb |
|
| Sevoflurane--nitrous oxide anaesthesia supplemented with remifentanil: effect on recovery and cognitive function. | 2001 Feb |
|
| Remifentanil in cardiac surgery. | 2001 Feb |
|
| The use of esmolol as an alternative to remifentanil during desflurane anesthesia for fast-track outpatient gynecologic laparoscopic surgery. | 2001 Feb |
|
| Remifentanil and controlled hypotension; comparison with nitroprusside or esmolol during tympanoplasty. | 2001 Jan |
|
| Recirculatory pharmacokinetics and pharmacodynamics of rocuronium in patients: the influence of cardiac output. | 2001 Jan |
|
| Effect of remifentanil on pain and secondary hyperalgesia associated with the heat--capsaicin sensitization model in healthy volunteers. | 2001 Jan |
|
| Remifentanil versus meperidine for monitored anesthesia care: a comparison study in older patients undergoing ambulatory colonoscopy. | 2001 Jan |
|
| Esmolol is not an alternative to remifentanil for fast-track outpatient gynecologic laparoscopic surgery. | 2001 Jul |
|
| Recovery after remifentanil and sufentanil for analgesia and sedation of mechanically ventilated patients after trauma or major surgery. | 2001 Jun |
|
| Remifentanil- and fentanyl-based anesthesia for intraoperative monitoring of somatosensory evoked potentials. | 2001 Jun |
|
| [Alterations in left ventricular-arterial coupling and mechanical efficiency produced by remifentanil during cardiac anesthesia]. | 2001 Mar |
|
| A comparison of two constant-dose continuous infusions of remifentanil for severe postoperative pain. | 2001 Mar |
|
| Recovery profile and side effects of remifentanil-based anaesthesia with desflurane or propofol for laparoscopic cholecystectomy. | 2001 Mar |
|
| [Anesthesia in extreme obesity]. | 2001 May |
|
| [General anesthesia with remifentanil in two cases of emergency cesarean section]. | 2001 May |
|
| A patient with hypertrophic obstructive cardiomyopathy presenting for total knee replacement. | 2001 May |
|
| Remifentanil is a valuable alternative to contraindicated neuraxial analgesia in the parturients. | 2001 May |
|
| The efficacy and resource utilization of remifentanil and fentanyl in fast-track coronary artery bypass graft surgery: a prospective randomized, double-blinded controlled, multi-center trial. | 2001 May |
|
| A randomized double-blinded multicenter comparison of remifentanil versus fentanyl when combined with isoflurane/propofol for early extubation in coronary artery bypass graft surgery. | 2001 May |
|
| Haemodynamic changes and vasopressin release are not consistently associated with carbon dioxide pneumoperitoneum in humans. | 2001 May |
|
| A comparison of fentanyl, sufentanil, and remifentanil for fast-track cardiac anesthesia. | 2001 Oct |
|
| Remifentanil and fentanyl during anaesthesia for major abdominal and gynaecological surgery. An open, comparative study of safety and efficacy. | 2001 Sep |
|
| Potential hazard with syringe infusion pump. | 2001 Sep |
|
| The in vitro effects of remifentanil, sufentanil, fentanyl, and alfentanil on isolated human right atria. | 2001 Sep |
|
| Quantitative EEG changes associated with loss and return of consciousness in healthy adult volunteers anaesthetized with propofol or sevoflurane. | 2001 Sep |
Patents
Sample Use Guides
Usual Adult Dose for Anesthesia
Induction of Anesthesia: Continuous IV infusion: 0.5 to 1 mcg/kg/min. If endotracheal intubation is to occur in less than 8 minutes, an initial dose of 1 mcg/kg may be administered over 30 to 60 seconds.
Maintenance of Anesthesia: With Nitrous Oxide, 0.4 mg/kg/min by continuous IV infusion.
Infusion dose range: 0.1 to 2 mcg/kg/min.
Supplemental IV bolus: 1 mcg/kg every 2 to 5 minutes.
Route of Administration:
Intravenous
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C67413
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
||
|
WHO-VATC |
QN01AH06
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
||
|
WIKIPEDIA |
List_of_fentanyl_analogues
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
||
|
NDF-RT |
N0000175690
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
||
|
WHO-ATC |
N01AH06
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
||
|
DEA NO. |
9739
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
||
|
NDF-RT |
N0000175684
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
||
|
NCI_THESAURUS |
C1506
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C66513
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
P10582JYYK
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
DB00899
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
CHEMBL1005
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
M9521
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | Merck Index | ||
|
2363
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
Remifentanil
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
132875-61-7
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
REMIFENTANIL
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
SUB10272MIG
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
8802
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
7292
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
C071741
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
6924
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
73032
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | RxNorm | ||
|
REMIFENTANIL
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | Remifentanil is used for sedation as well as combined with other medications for use in general anesthesia. Remifentanil is used as an opioid analgesic that has a rapid onset and rapid recovery time. It has been used effectively during craniotomies, spinal surgery, cardiac surgery, and gastric bypass surgery. While opiates function similarly, with respect to analgesia, the pharmacokinetics of remifentanil allows for quicker post-operative recovery. | ||
|
100000089165
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
DTXSID00157826
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
60815
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
P10582JYYK
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE INACTIVE (PARENT)
SALT/SOLVATE (PARENT)
